Novo Nordisk offers discounted Wegovy through direct-to-consumer pharmacy
Novo Nordisk’s Wegovy weight reduction drug has seen a meteoric rise in recognition.
Novo Nordisk on Wednesday mentioned it’s going to provide its weight reduction drug Wegovy for lower than half of its typical value per thirty days via a brand new direct-to-consumer on-line pharmacy.
The cash-pay providing is offered to thousands and thousands of sufferers with out insurance coverage protection for the blockbuster injection, akin to these with Medicare. The pharmacy, known as NovoCare, will enable sufferers to pay $499 in money per thirty days for the weekly drug.
Wegovy’s listing value earlier than insurance coverage and different rebates is nearly $1,350 per thirty days.
The Danish drugmaker’s transfer follows the same technique from its essential rival Eli Lilly. The 2 firms are preventing to dominate the marketplace for so-called GLP-1s, which mimic sure intestine hormones to suppress urge for food and regulate blood sugar.
Eli Lilly in January 2024 launched its personal direct-to-consumer on-line pharmacy, LillyDirect, to assist sufferers entry its weight reduction drug Zepbound.
The web site permits eligible sufferers to get a prescription via a telehealth supplier and might present house supply. Extra just lately, LillyDirect additionally began providing Zepbound in single-dose vials which can be half and even much less of its typical $1,000 month-to-month listing value.
This story is growing. Please examine again for updates.
